Based on these data, on August 02, 2024, the FDA granted accelerated approval of afamicel for adults with unresectable or metastatic SS who have received prior chemotherapy; are HLA-A*02:01P, -A*02:02P, -A*02:03P or -A*02:06P-positive; and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices [74]. Here, MAGEA4 is linked to synovial sarcoma.